the trial is positive, with an incredible hazard ratio of 0.21 and a huge difference between the two arms - 72% of patients are progression-free in the nivo + ipi compared to 14% in the chemotherapy arm at 24 mont...
CheckMate 142 是一项多中心、开放、非随机、多个队列的Ⅱ期研究,旨在评估纳武利尤单抗单药或纳武利尤单抗联合伊匹单抗治疗 MSI-H mCRC(转移性结直肠癌)的疗效和安全性,主要研究终点为 ORR,次要终点有 DCR、PFS、OS 等。 2017 年公布了纳...
MSI-H/dMMR 型 CRC 患者目前占全部 CRC 患者的 5% 左右[1],该类型属于 CRC 中的特殊群体,治疗手段和错配修复完整(pMMR)CRC 患者不同,具体表现为对于免疫治疗较为敏感。 具体在 mCRC 领域中,CheckMate-142 研究初步探索了双免疫方案是否可为 MSI-H/dMMR 患者带来良好疗效和长期生存。结果显示,纳武利尤单抗...
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the ...
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary.
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma.
A dual primary end point of progression-free survival in the phase 3 CheckMate-8HW trial evaluating nivolumab and ipilimumab in metastatic colorectal cancer has been met.
To our knowledge, CheckMate 8HW is the first randomised, phase 3 trial in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer to report superior progression-free survival and objective response rate with the dual-immune checkpoint inhibitors, nivolumab plus ipilimumab ...
PFS: The combination doubled median PFS (17.0 months vs. 8.3 months, respectively; HR 0.52; 95% CI: 0.43 to 0.64), the trial’s primary endpoint, compared to sunitinib. ORR: Nearly twice as many patients responded toOPDIVOin combination withCABOMETYXvs. sunitinib (54.8% ...